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Michael J. Yunes, MD,15 and Gregory M.M. Videtic, MD16

Abstract

Pretreatment evaluation is performed to determine the number, location, and size of the brain metastases and
magnetic resonance imaging (MRI) is the recommended imaging technique, particularly in patients being
considered for surgery or stereotactic radiosurgery. A contiguous thin-cut volumetric MRI with gadolinium with
newer gadolinium-based agents can improve detection of small brain metastases. A systemic workup and
medical evaluation are important, given that subsequent treatment for the brain metastases will also depend on
the extent of the extracranial disease and on the age and performance status of the patient. Patients with
hydrocephalus or impending brain herniation should be started on high doses of corticosteroids and evaluated for possible neurosurgical intervention. Patients with moderate symptoms should receive approximately
4–8 mg/d of dexamethasone in divided doses. The routine use of corticosteroids in patients without neurologic
symptoms is not necessary. There is no proven benefit of anticonvulsants in patient without seizures. The
American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical
conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and
review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging
and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert
opinion may be used to recommend imaging or treatment.
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SUMMARY OF LITERATURE REVIEW

images) could be considered for screening purposes. In 183
patients with newly diagnosed non–small-cell lung cancer
(NSCLC), this limited MRI detected brain metastases in
approximately 20% of patients. In an historical control group
of similar patients with NSCLC who underwent limited MRI
only if they had neurologic signs or symptoms at the time of
diagnosis, 6% were found to have brain metastases. The cost
of the limited MRI was approximately 40% of the estimated
cost of the normal diagnostic MRI. For a patient with neurologic signs or symptoms, a CT with contrast is reasonable
as a first test, but an MRI is required if the decision regarding
treatment requires knowledge of the exact number of metastases (see Variant 1).
Several older studies have demonstrated that the dose of
intravenous contrast used for MRI is important in determining the number of lesions detected as well as the confidence
level associated with the radiologic interpretation.4,5,10,11
Yuh et al.11 reported that high-dose contrast (0.3 mmol/kg
gadolinium) is superior in lesion detection without any increase in serious toxicity compared to standard-dose contrast
(0.1 mmol/kg gadolinium). However, there is also evidence
that the strength of the MRI magnet is important in the ability
to detect brain metastases.12,13 Ba-Ssalamah et al.12 analyzed
the subjective assessment of MRI with standard-dose or
triple-dose contrast in both 1.5T and 3T magnetic fields.
Improved images were obtained with both higher dose of
contrast and higher magnet strength. The double-dose concept was introduced using gadolinium.11 Since then, new
contrast media have become available and seem to offer
significantly greater diagnostic information and lesion enhancement even at lower doses.14 Therefore, the concept of
double-dose contrast has more or less become obsolete, even
with 1.5T magnets, with the availability of the newer contrast
agents (see Variant 2). Small studies have suggested that
other tests such as dynamic contrast-enhanced MRI, perfusion imaging, and magnetic resonance spectroscopy may
help differentiate between brain metastases and high-grade
gliomas.15,16
The bulk of the literature regarding the use of brain CT or
MRI for staging purposes has dealt with lung cancer.
Nevertheless, there is still no general agreement on when to
use CT or MRI as part of the initial staging evaluation for a
patient newly diagnosed with lung cancer. The decision may
vary with the type and stage of lung cancer. One prospective
study found that MRI did not change the initial stage of
asymptomatic patients with small-cell lung cancer.17 The
only patients found to have asymptomatic brain metastases
already had extensive stage disease demonstrated by other
tests such as a positive bone scan or liver metastases on CT
scan of the abdomen. Although brain MRI appears to be a
superior imaging technique compared with brain CT, CT is
still widely used as a staging procedure because of its easy
accessibility and lower cost. A retrospective study reported
by Ferrigno and Buccheri18 concluded that 10% of patients
with otherwise operable NSCLC had brain metastases identified on CT scans of the brain. The absence of neurologic
symptoms did not exclude brain metastases since 64% of
patients with metastases detected by CT were asymptomatic.
Conversely, Hooper et al.19 found that CT scans did not reveal unsuspected brain metastases in patients without strong
evidence of disseminated disease, such as neurologic signs or
symptoms, bone pain, or elevated serum calcium. Hooper

Introduction

T

he pretreatment evaluation for brain metastases
occurs either as part of the staging investigations in a
patient who has known systemic cancer or in a patient who
has cerebral or cerebellar symptoms, with or without known
systemic cancer. In either case, the evaluation is critical when
the presence of brain metastases would alter the overall oncologic management. The patient’s clinical symptomatology
and overall oncologic picture as well as the findings on diagnostic imaging of the brain will determine the appropriate
treatment for brain metastases. Although brain metastases
can arise from virtually any primary cancer, lung and breast
are the two most common primary sites of cancer in patients
presenting with brain metastases. Other common histologies
include melanoma, renal cell carcinoma, and colorectal
cancer. The literature regarding pretreatment evaluation and
management is dominated by patients with these primary
malignancies.
The choice of treatment for brain metastases is often based
on patient symptomatology, histology, location, and number
of metastases identified on imaging studies.1–3 Contrastenhanced magnetic resonance imaging (MRI) is the imaging
test of choice in the patient with suspected brain metastases if
surgery or radiosurgery is being considered.4,5 Otherwise,
computed tomography (CT) with contrast injection is a reasonable study, albeit less sensitive than MRI.
CT/MRI

During the CT era as many as 50% of patients with
brain metastases were found to have a single metastasis.6
However, it is almost certain that the current percentage
is lower, given the increased sensitivity of modern MRI,
especially when a volumetric sequence with contiguous
thin cuts is included. Current patient data, acquired with
modern CT and MRI technology, indicate that approximately 20% of patients thought to have a single brain
metastasis based on CT actually are found to have multiple lesions on MRI.7 However, CT with contrast remains
the best imaging option for investigation of brain metastasis in patients with automatic implantable cardioverter
defibrillators or pacemakers. If treatment is to be determined according to the number of brain metastases, MRI
with pregadolinium T1-weighted and T2-weighted sequences and postgadolinium T1-weighted imaging, preferably a thin-cut contiguous volumetric sequence in axial,
coronal, and sagittal planes, is recommended.
Fluid-attenuated inversion-recovery (FLAIR) sequences
have also been shown to complement, but not replace,
contrast-enhanced T1 sequences, and can be correlated with
the T1 sequences to determine whether a punctuate contrastenhanced lesion is a metastatic lesion, which frequently
shows signal intensity on FLAIR imaging. Contiguous thin
slices without skips are necessary to ensure that small lesions
are detected.8 To reduce costs, a more limited MRI can be
done when the intent is merely to determine whether brain
metastases are present.9
Kim et al.9 demonstrated that a limited MRI scan (T2 axial,
proton density axial, and contrast-enhanced T1 sagittal
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Table 1. ACR Appropriateness Criteria Pre-Irradiation Evaluation
and Management of Brain Metastases
Clinical Condition: Pre-Irradiation Evaluation and Management of Brain Metastases
Variant 1: 50-year-old patient with newly diagnosed cancer of any stage and new intracranial signs or symptoms.
Radiologic procedure

Rating

Comments

MRI head with standard dose
contrast

9

CT head with contrast

6

Several members of the panel considered MRI needed only if the exact number of
metastases is necessary to make decisions regarding stereotactic radiosurgery
or surgery.
Approximately 50% of cases would still need MRI to determine exact number of
metastases and determine if patient is a good candidate for stereotactic
radiosurgery or surgery. If the CT is negative it is very likely that the
radiologist will recommend an MRI since this patient has new intracranial
signs or symptoms. CT was thought by many to be indicated only in those
patients in whom MRI is contraindicated or unavailable.

Rating Scale: 1, 2, 3: usually not appropriate; 4, 5, 6: may be appropriate; 7, 8, 9: usually appropriate

Variant 2: 50-year-old patient with newly diagnosed non–small-cell lung cancer with resectable primary
and CT evidence of solitary brain metastasis.
Radiologic procedure
MRI head with standard dose
contrast
MRI head with high dose
contrast

Rating

Comments

9
6

High-dose contrast may not be needed with the availability of new gadoliniumbased contrast agents that offer significantly greater diagnostic information and
lesion enhancement even at lower doses.

Rating Scale: 1, 2, 3: usually not appropriate; 4, 5, 6: may be appropriate; 7, 8, 9: usually appropriate

Variant 3: 45-year-old patient with metastatic melanoma and newly diagnosed multiple small supratentorial brain
metastases. On treatment with ipilimumab. Mild edema on imaging. No hydrocephalus, neurologic
symptoms, or history of seizures.
Radiologic procedure

Rating

Comments

Corticosteroids 4–8 mg/d

2

Corticosteroids 16 mg/d

2

Anticonvulsants
(prophylactic)

2

Corticosteroids are not absolutely indicated and may interfere with efficacy of
ipilimumab.
Corticosteroids are not absolutely indicated and may interfere with efficacy of
ipilimumab.
In a patient with no history of seizures, the use of prophylactic anticonvulsants is
deemed inappropriate.

Rating Scale: 1, 2, 3: usually not appropriate; 4, 5, 6: may be appropriate; 7, 8, 9: usually appropriate

Variant 4: 50-year-old patient with non–small-cell lung cancer and multiple supratentorial brain metastases.
Mild edema on imaging. No hydrocephalus. Mild neurologic symptoms present. No history of seizures.
Treatment

Rating

Corticosteroids 4–8 mg/d
Corticosteroids 16 mg/d

8
7

Anticonvulsants
(prophylactic)

3

Comments
Some panel members recommended starting at 16 mg/day and then lowering to
4–8 mg after a few days.
In a patient with no history of seizures, the use of prophylactic anticonvulsants is
deemed inappropriate.

Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate
MRI, magnetic resonance imaging; CT, computed tomography.
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et al.19 did not address the utility of CT scans in otherwise
operable patients, and it is possible that their patient group
had a more advanced stage of disease at presentation than that
seen by Ferrigno and Buccheri,18 which would account for
the different conclusions reached by the two authors. A
prospective study of brain CT in 105 patients with potentially
resectable NSCLC cancer found brain metastases in 4.8% of
patients.20 The authors concluded that the cost savings
achieved by avoiding thoracotomy was far larger than the
cost associated with the CT scans.
Positron Emission Tomography

Positron emission tomography (PET) with fluorine-18-2fluoro-2-deoxy-D-glucose (FDG) has been evaluated as a
means of identifying brain metastases.21,22 PET studies in
small numbers of patients have been associated with low
sensitivity and specificity rates in the detection of brain metastases. PET scans have also been tested as a means of differentiating various abnormalities already detected by more
conventional imaging studies such as CT or MRI. Wholebody FDG-PET is more useful in locating the primary lesion
and sites of extracranial metastases in a patient with documented brain metastases. The lack of sensitivity or specificity
of cerebral FDG-PET is likely due to the large background of
glucose activity within the brain. Alternative tracers to FDG
such as 3-deoxy-3-fluorothymidine, thallium-201, or 11Cmethionine PET may in the future prove to be more useful in
the imaging of brain metastases.23,24
Pathologic Confirmation

Several authors have sought to determine whether histologic confirmation is required following the identification of
a suspected solitary metastasis or multiple brain metastases.3,25 In one study in which stereotactic biopsy or resection
was performed in patients with suspected solitary brain metastases, 11% of these patients were found to have other tumor histology or lesions of infectious or inflammatory
origin.3 Stereotactic biopsy is equivalent to resection in determining the correct tissue diagnosis in most patients if an
appropriate number of biopsies are obtained and confirmation
is immediately available by frozen section histology. Although multifocal malignant gliomas are relatively uncommon compared with brain metastases, the two clinical
conditions may be difficult to distinguish on the basis of
current conventional imaging studies.25 However, new MRI
methods (perfusion and magnetic resonance spectroscopy)
have shown improvement in specificity.15,16 Identification of
a solitary brain lesion in a patient with a controlled extracranial primary cancer with no other sites of disease on
systemic evaluation should be followed by MRI with increased dose of contrast and, if no additional lesions are
identified, histologic verification. In patients found to have
multiple brain lesions with imaging characteristics compatible with metastases, the decision whether to pursue histologic
confirmation is based on the clinical picture. Patients with
progressive extracranial cancer are seldom subjected to histologic confirmation of multiple brain lesions or new solitary
lesions.
It is common practice to obtain a neurosurgical opinion
regarding surgical intervention to debulk or completely resect brain metastases in a patient presenting with hydro-
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cephalus due to a posterior fossa metastasis or in a patient
with impending cerebral or cerebellar herniation from mass
effect caused by a bulky brain metastasis.
Steroids

Although clinical experience has established the effectiveness of corticosteroids such as dexamethasone in reducing symptoms and MRI evidence of peritumoral edema, the
need for corticosteroids in all patients with brain metastases
and the appropriate dose of such medication are points of
some research and controversy.26,27 Sturdza et al.27 surveyed
38 oncologists at a single large cancer center who managed
patients with brain metastases to document the use of steroids
and the frequency of their side effects. Ninety percent of
physicians responded to the survey. Fifty-five percent determined the dose of steroid according to the presence or
absence of neurological symptoms. The other 45% routinely
started 4 mg dexamethasone four times per day. Sixty percent
tapered the steroid dose in the 4 weeks following completion
of whole-brain radiation therapy.
Early studies concluded that patients with newly diagnosed
brain metastases should be placed on steroids prior to wholebrain radiation therapy using unconventional radiation dose/
fractionation regimens.28,29 For example, in one prospective
clinical trial in which various whole-brain radiation dose/
fraction schedules were used, steroids were started only when
there was concern about high intracranial pressure.29 The
results of this study suggest that patients undergoing wholebrain radiation therapy with high doses per fraction should be
started on steroids prior to treatment. Twenty-seven percent of patients treated with a single dose of 10 Gy singlefraction whole-brain radiation therapy experienced acute
signs or symptoms of increased intracranial pressure. This
dose/fractionation of whole-brain radiation therapy is not in
common use at this time. Another study, conducted by the
Radiation Therapy Oncology Group nearly 2 decades ago,
found that patients with moderate neurologic signs or symptoms experienced more rapid improvement in their clinical
state when radiation treatment was accompanied by steroids.28 However, steroids did not result in prolongation of
progression-free survival or overall survival.
Despite the acknowledged benefits of steroids in reducing
edema and alleviating symptoms, the acute and chronic side
effects of dexamethasone cannot be ignored. A randomized
study comparing dosages of 4, 8, and 16 mg of dexamethasone per day found no advantage to higher dosages compared
with 4 mg/d in patients with no evidence of impending herniation.30 Steroid-related toxicity was more common at the
higher doses. There was, however, a trend toward improved
performance 28 days after starting dexamethasone in patients
on high doses of steroids. This improvement in the high-dose
group was attributed to the early steroid taper in the low-dose
group, which began on the seventh day of cranial irradiation
and led to clinical deterioration in some patients. Based on
this observation, the authors recommended 4 mg/d without a
dose taper for 28 days in patients without symptoms or signs
of mass effect.
Hempen et al.31 studied 138 patients with primary or
metastatic brain tumors treated with radiation therapy.
Ninety-one patients with brain metastases were treated with
standard-fraction whole-brain radiation therapy for 2–3
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weeks. Most of these patients received dexamethasone with
tapering doses for a mean duration of 6.9 weeks. Clinical
improvements possibly attributable to dexamethasone were
observed in 33% of patients shortly after dexamethasone was
initiated, in 44% of patients during radiotherapy, and in 11%
of patients after radiotherapy. However, side effects possibly
attributable to dexamethasone were frequently observed, including hyperglycemia (47%), peripheral edema (11%),
psychiatric disorder (10%), oropharyngeal candidiasis (7%),
Cushing syndrome (4%), muscular weakness (4%), and pulmonary embolism (2%). Among 13 patients treated without
dexamethasone, treatment was well tolerated except in one
patient with initial brain stem symptoms.
Patients with brain metastases from melanoma and renal
cell carcinoma deserve separate considerations. Patients with
these cancers are frequently treated with agents such as interleukin-2 (melanoma and renal cell carcinoma),32 ipilimumab (melanoma),33 and sunitinib (renal cell carcinoma),
whose anticancer efficacy may be lessened when a corticosteroid is taken concurrently. It is crucial that the radiation
oncologist communicates with the treating medical oncologist to discuss the pros and cons of using a corticosteroid,
especially when the patient is only very mildly symptomatic
(see Variant 3).
In summary, there is little compelling evidence to support
the routine use of steroids in the newly diagnosed patient with
brain metastases who has no neurological signs or symptoms.
Likewise, there is no compelling evidence that, in the absence
of neurologic symptoms, steroids should be started simply
because the patient is about to start radiation therapy. Steroids
cause toxicity and may mitigate the therapeutic effects of
systemic therapy for renal cell carcinoma and melanoma.
Therefore, any recommendation for steroids must be rendered in light of this fact. For patients with minimal neurologic symptoms the panel recommends either starting with
4–8 mg/d or starting with 16 mg/d but tapering after a few
days. In all cases, steroids should be tapered as clinically
indicated and tolerated (see Variant 4).

LO ET AL.

after brain tumor diagnosis in patients with primary as
compared to metastatic brain tumors. More than 20% of patients had side effects severe enough to warrant a change in or
discontinuation of the anticonvulsants. A subsequent randomized study of prophylactic anticonvulsants versus observation by Forstyth et al.35 reached a similar conclusion
regarding the lack of benefit of prophylactic anticonvulsants.
One clinical situation in which a benefit to prophylactic
anticonvulsants has been suggested is in the patient with
brain metastases from malignant melanoma. A retrospective
study reported by Byrne et al.38 found that prophylactic anticonvulsants in patients with brain metastases from metastatic melanoma reduced the subsequent seizure frequency
from 37% to 17%. Possible explanations for the high incidence of seizures in patients with brain metastases from
melanoma, as opposed to other histologies, include the tendency for these metastases to be located in the superficial
cerebral cortex rather than at the junction between gray and
white matter. The meta-analysis by Glantz et al.34 did not
indicate a significant benefit to anticonvulsants in patients
with malignant melanoma brain metastases but concluded
that further prospective studies of prophylactic anticonvulsants were warranted in this subgroup. The panel consensus is
to not start anticonvulsants prophylactically in patients with
brain metastases due to any primary cancer, including melanoma (see Variant 3 and Variant 4).
Physicians should also be aware of the potential interaction
between anticonvulsants and chemotherapy. Anticonvulsants
that induce the P450 system of hepatic metabolism can result
in a clinically significant reduction of plasma levels of chemotherapies that are metabolized by this system. Anticonvulsants that do not induce this system are available and
should be selected if this is a concern.
Summary



Prophylactic Anticonvulsants

Another controversy revolves around the need to initiate
prophylactic anticonvulsants in patients with brain metastases. A meta-analysis estimated that 15% of patients with
brain metastases present with seizures, and most of them are
found to have supratentorial lesions.34 Patients who present
with seizures or who develop seizures during therapy should
be started on antiseizure medications. Randomized prospective studies have found no significant reduction in the incidence of first seizures in brain tumor patients placed on
prophylactic anticonvulsants.35–37 New onset of seizures was
experienced by approximately 25% of patients treated with
prophylactic anticonvulsants, not significantly different than
the percentage of patients experiencing new onset of seizures
in the control arm. The meta-analysis by Glantz et al.34
concluded that there was no evidence that prophylactic anticonvulsants significantly decreased the incidence of first
seizure. In the aggregate, these 12 studies included in the
meta-analysis recorded a 26% incidence of seizures at or
before brain tumor diagnosis (range, 14%–51%), and a 19%
incidence of seizures after brain tumor diagnosis (range,
10%–45%). Seizures were more common both before and














Pretreatment evaluation should determine the number,
location, and size of the brain metastases.
MRI is the recommended imaging technique, particularly
in patients being considered for surgery or radiosurgery.
Contiguous thin-cut volumetric MRI with gadolinium
can improve detection of small brain metastases.
Use of double-dose or triple-dose contrast at the time of
MRI may be no longer necessary with the availability
of newer gadolinium-based agents.
A noncontrast scan should accompany the contrast scan
to exclude hemorrhage or fat as the cause of the high
signal on postcontrast imaging.
A systemic workup and medical evaluation are important, given that subsequent treatment for the brain
metastases will also depend on the extent of the extracranial disease and on the age and performance
status of the patient.
Patients with hydrocephalus or impending brain herniation should be started on high doses of corticosteroids
and evaluated for possible neurosurgical intervention.
Patients with moderate symptoms should receive approximately 4–8 mg/d of dexamethasone in divided doses.
The routine use of corticosteroids in patients without
neurologic symptoms is not necessary.
There is no proven benefit of anticonvulsants in the
patient who has not experienced seizures.
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Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD,
Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den
Berge D, Collette S, Collette L, Mueller RP: Adjuvant
whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin
Oncol 2011;29:134–141.
3. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar
LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ,
Gillin MT, Mohideen N, Hahn CA, Chang EL: Radiotherapeutic and surgical management for newly diagnosed
brain metastasis(es): An American Society for Radiation
Oncology evidence-based guideline. Pract Radiat Oncol 2012;
2:210–225.
4. Akeson P, Larsson EM, Kristoffersen DT, Jonsson E,
Holtas S: Brain metastases—Comparison of gadodiamide
injection-enhanced MR imaging at standard and high dose,
contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 1995;36:300–306.
5. Kuhn MJ, Hammer GM, Swenson LC, Youssef HT,
Gleason TJ. MRI evaluation of ‘‘solitary’’ brain metastases
with triple-dose gadoteridol: Comparison with contrastenhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients. Comput Med
Imaging Graph 1994;18:391–399.
6. Nussbaum ES, Djalilian HR, Cho KH, Hall WA: Brain
metastases. Histology, multiplicity, surgery, and survival.
Cancer 1996;78:1781–1788.
7. Schellinger PD, Meinck HM, Thron A: Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999;44:275–281.
8. Nagai A, Shibamoto Y, Mori Y, Hashizume C, Hagiwara
M, Kobayashi T: Increases in the number of brain metastases detected at frame-fixed, thin-slice MRI for
gamma knife surgery planning. Neuro Oncol. 2010;12:
1187–1192.
9. Kim SY, Kim JS, Park HS, Cho MJ, Kim JO, Kim JW,
Song CJ, Lim SP, Jung SS: Screening of brain metastasis
with limited magnetic resonance imaging (MRI): Clinical

13.

14.

15.

16.

17.

18.
19.

20.

21.

22.

implications of using limited brain MRI during initial
staging for non-small cell lung cancer patients. J Korean
Med Sci 2005;20:121–126.
Runge VM, Wells JW, Nelson KL, Linville PM: MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. J Magn Reson Imaging
1994;4:669–673.
Yuh WT, Fisher DJ, Runge VM, Atlas SW, Harms SE,
Maravilla KR, Mayr NA, Mollman JE, Price AC: Phase III
multicenter trial of high-dose gadoteridol in MR evaluation
of brain metastases. AJNR Am J Neuroradiol 1994;15:
1037–1051.
Ba-Ssalamah A, Nobauer-Huhmann IM, Pinker K, Schibany N, Prokesch R, Mehrain S, Mlynárik V, Fog A,
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